AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 10024611
Drug: Prior protein
RxNorm normalized name: protein C
DrugBank: Protein C (DB11312)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prior protein intake of 2.0 g protein. kg‐1. d‐1
Trial: 10024611
Drug: Amino acid‐based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amino acid‐based formula diet containing 1 g protein. kg‐1. d‐1
Trial: 6417996
Drug: Intermittent nasogastric
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intermittent nasogastric feeding (2-h bolus administration)
Trial: 21523892
Drug: Intravenous bolus
RxNorm normalized name: SET,INFUSION,BOLUS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous bolus plus infusion of tirofiban (n = 24)
Trial: 15285862
Drug: Single high
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single high dose steroid treatment in addition to intravenous antibiotic therapy
Trial: 15285862
Drug: Intravenous antibiotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous antibiotic therapy with a single dose placebo
Trial: 2344503
Drug: Bendrofluazide 10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bendrofluazide 10 mg
Trial: 3316309
Drug: Hydrochlorothiazide 25
RxNorm normalized name: hydrochlorothiazide 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydrochlorothiazide 25 mg + Amiloride 2.5 mg
Trial: 18407793
Drug: CoQ(10) 100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CoQ(10) 100 mg, riboflavin 10 mg and niacin 50 mg (CoRN) along with tamoxifen (TAM) 10 mg twice a day for 45 days (Group IV)
Trial: 18407793
Drug: CoQ(10) 100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CoQ(10) 100 mg, riboflavin 10 mg and niacin 50 mg (CoRN) along with tamoxifen (TAM) 10 mg twice a day for 90 days (Group V)
Trial: 18407793
Drug: Tamoxifen (TAM)
DrugBank: Tamoxifen (DB00675)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tamoxifen (TAM) 10 mg twice a day
Trial: 16422829
Drug: Placebo (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (10 mL saline)
Trial: 23585286
Drug: Sulpiride 100
RxNorm normalized name: sulpiride 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sulpiride 100 mg dose
Trial: 29943744
Drug: Parenteral Vitamin
RxNorm normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Parenteral Vitamin D supplementation
Trial: 21617262
Drug: Chamomile solution
RxNorm normalized name: Chamomile
DrugBank: Chamomile (DB14357)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chamomile solution (twice-a-day application)
Trial: 21617262
Drug: Hydrocortisone 1%
RxNorm normalized name: HYDROCORTISONE 1% OINT
DrugBank: Hydrocortisone acetate (DB14539)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hydrocortisone 1% ointment (once-a-day application)
Trial: 16894619
Drug: Venlafaxine ER
RxNorm normalized name: Venlafaxine ER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Venlafaxine ER (75 mg/day or 150 mg/day)
Trial: 16894619
Drug: Active treatment
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active treatment (Venlafaxine ER or Paroxetine)
Trial: 15215096
Drug: Fluconazole 400
RxNorm normalized name: fluconazole 400 MG in 200 ML Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluconazole 400 mg per day
Trial: 11800414
Drug: Captopril plus
RxNorm normalized name: Captopril
DrugBank: Captopril (DB01197)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Captopril plus canreonate (25 mg/day)
Trial: 2658637
Drug: Ivermectin treatment
RxNorm normalized name: Ivermectin
DrugBank: Ivermectin (DB00602)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ivermectin treatment (100, 150, or 200 micrograms/kg at 1 or 2 year intervals)
Trial: 29641242
Drug: Acupuncture intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Acupuncture intervention (weekly or biweekly individualized treatments)
Trial: 26141682
Drug: Internet-supported cognitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Internet-supported cognitive behavioral therapy
Trial: 12929019
Drug: Propranolol administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propranolol administration (group B, n = 20)
Trial: 10720043
Drug: Nateglinide (60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nateglinide (60 mg and 180 mg or 120 mg and 240 mg)
Trial: 1547045
Drug: 0.375% bupivacaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.375% bupivacaine 10 ml alone
Trial: 1547045
Drug: 0.375% bupivacaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.375% bupivacaine 10 ml combined with fentanyl 100 micrograms
Trial: 4087369
Drug: Transfusion at
RxNorm normalized name: rose bengal AT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transfusion at 2 ml/min (Group A)
Trial: 4087369
Drug: Transfusion at
RxNorm normalized name: rose bengal AT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transfusion at 5 ml/min (Group B)
Trial: 4087369
Drug: Transfusion at
RxNorm normalized name: rose bengal AT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transfusion at 10 ml/min (Group C)
Trial: 4087369
Drug: Transfusion at
RxNorm normalized name: rose bengal AT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transfusion at 5 ml/min with 40 mg furosemide (Group D)
Trial: 29846530
Drug: Andecaliximab 150
RxNorm normalized name: Andecaliximab
DrugBank: Andecaliximab (DB17564)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Andecaliximab 150 mg every 2 weeks (Q2W)
Trial: 29846530
Drug: Andecaliximab 150
RxNorm normalized name: Andecaliximab
DrugBank: Andecaliximab (DB17564)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Andecaliximab 150 mg weekly (QW)
Trial: 29846530
Drug: Andecaliximab 300
RxNorm normalized name: Andecaliximab
DrugBank: Andecaliximab (DB17564)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Andecaliximab 300 mg weekly (QW)
Trial: 27515515
Drug: Immediate-release melatonin
RxNorm normalized name: melatonin Extended Release Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediate-release melatonin (3 mg) administered daily at 21:00 ± 1 h from day 1 to day 28 of admission
Trial: 21203698
Drug: Low-level laser
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-level laser therapy (LLLT) (830 nm, 15 mW, 12 J/cm²) daily from the 1st day until the end of RT for 5 consecutive days
Trial: 21203698
Drug: Aluminum hydroxide
RxNorm normalized name: Aluminum Hydroxide
DrugBank: Aluminum hydroxide (DB06723)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aluminum hydroxide (AH) 310 mg/5 mL, 4 times/day throughout the duration of RT
Trial: 14667696
Drug: Living kind
RxNorm normalized name: Typhoid Vaccine Live
DrugBank: Typhoid Vaccine Live (DB11050)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Living kind concepts at different hierarchical levels (e.g. tree, oak)
Trial: 11697755
Drug: Intravenous lorazepam
RxNorm normalized name: Lorazepam
DrugBank: Lorazepam (DB00186)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous lorazepam (2 mg)
Trial: 11697755
Drug: Intramuscular lorazepam
RxNorm normalized name: Lorazepam
DrugBank: Lorazepam (DB00186)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intramuscular lorazepam (2 mg)
Trial: 11697755
Drug: All routes
RxNorm normalized name: All Clear
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All routes (Intranasal, Intravenous, Intramuscular)
Trial: 8180641
Drug: DTaP vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DTaP vaccine (0.5 mL, intramuscularly)
Trial: 8180641
Drug: DTwP vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DTwP vaccine (0.5 mL, intramuscularly)
Trial: 8180641
Drug: Both DTaP
RxNorm normalized name: Bothrops atrox venom
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both DTaP and DTwP vaccines
Trial: 3282463
Drug: Gallium nitrate
RxNorm normalized name: Gallium Nitrate
DrugBank: Gallium citrate (DB17893)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Gallium nitrate 200 mg/m2 body surface area for 5 days by continuous intravenous infusion
Trial: 3282463
Drug: Calcitonin 8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcitonin 8 IU/kg body weight every 6 hours for 5 days by intramuscular injection
Trial: 28929258
Drug: Serotonin (5-HT)
RxNorm normalized name: serotonin
DrugBank: Serotonin (DB08839)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Serotonin (5-HT) administered via intraventricular injection
Trial: 28929258
Drug: Dopamine (DA)
DrugBank: Dopamine (DB00988)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dopamine (DA) administered via intraventricular injection
Trial: 26659927
Drug: Continuous intravenous
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous intravenous infusion of terlipressin (TERLI-INF group) at an initial dose of 2 mg/day
Trial: 26659927
Drug: Intravenous boluses
RxNorm normalized name: phenylbutazone
DrugBank: Phenylbutazone (DB00812)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous boluses of terlipressin (TERLI-BOL group) at an initial dose of 0.5 mg every 4 hours
Trial: 26659927
Drug: Continuous intravenous
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous intravenous infusion of terlipressin (TERLI-INF group)
Trial: 26659927
Drug: Intravenous boluses
RxNorm normalized name: phenylbutazone
DrugBank: Phenylbutazone (DB00812)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous boluses of terlipressin (TERLI-BOL group)
Trial: 20350430
Drug: Gradual drug
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gradual drug withdrawal after a 12-week treatment course
Trial: 20350430
Drug: Immediate drug
RxNorm normalized name: IR-3535
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediate drug withdrawal
Trial: 18444136
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of vitamin E and selenium
Trial: 14650707
Drug: 20-mg enalapril
RxNorm normalized name: enalapril 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20-mg enalapril tablets (test product)
Trial: 14650707
Drug: 20-mg enalapril
RxNorm normalized name: enalapril 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20-mg enalapril tablets (reference product)
Trial: 9170118
Drug: Cyclandelate (Natil,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyclandelate (Natil, 1,600 mg/day)
Trial: 1313163
Drug: Diet +
RxNorm normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diet + glucomannan (approx. 4 g/die in 3 doses)
Trial: 1313163
Drug: Hypocaloric diet
RxNorm normalized name: Hydrochloric Acid
DrugBank: Hydrochloric acid (DB13366)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hypocaloric diet therapy alone
Trial: 31204473
Drug: 3-Hydroxybenzo[a]pyrene glucuronide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3-Hydroxybenzo[a]pyrene glucuronide (BaP-3-G)
Trial: 17585375
Drug: Topical application
RxNorm normalized name: Talc Topical application Powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical application of 0.5% timolol maleate
Trial: 7887637
Drug: Cisplatin-based combination
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cisplatin-based combination chemotherapy followed by chest irradiation
Trial: 7887637
Drug: Radiotherapy in
RxNorm normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Radiotherapy in combination with chemotherapy
Trial: 3040923
Drug: Alternating chemotherapy
RxNorm normalized name: yellow fever virus strain 17D-204 live antigen
DrugBank: Yellow fever vaccine (DB10805)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alternating chemotherapy
Trial: 7887637
Drug: Weekly chemotherapy
RxNorm normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Weekly chemotherapy (increased dose intensity)
Trial: 7887637
Drug: New drugs
FDA approved: no
EMA approved: no
PMDA approved: no
Description: New drugs (CPT-11, taxol, axotere, vinorelbine, gemcitabine)
Trial: 1919301
Drug: Oral iron
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral iron absorption
Trial: 30819228
Drug: mHealth intervention
RxNorm normalized name: smallpox vaccine live, New York City Board of Health vaccinia strain Injectable Solution [ACAM2000]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: mHealth intervention (reminder via cellphone text message/call or bottle-based flash/alarm, plus monthly counseling)
Trial: 30819228
Drug: Usual care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Usual care (standard counseling at routine monthly clinic visits)
Trial: 29291768
Drug: Mothering from
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mothering from the Inside Out (MIO) treatment
Trial: 27568506
Drug: Internet-based smoking
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Internet-based smoking cessation intervention combined with tele-health medication clinic for nicotine replacement therapy (NRT)
Trial: 25306746
Drug: Amaltea goat's
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amaltea goat's milk 200 ml/day during basic therapy
Trial: 25306746
Drug: Traditional basic
RxNorm normalized name: Basic Fuchsin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Traditional basic dietary therapy
Trial: 20153029
Drug: Budesonide/formoterol maintenance
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Budesonide/formoterol maintenance and reliever therapy (Symbicort SMART Turbuhaler)
Trial: 15459602
Drug: N-acetylcysteine (NAC)
DrugBank: Acetylcysteine (DB06151)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: N-acetylcysteine (NAC) 2000 mg/dose, n = 95
Trial: 10937408
Drug: Hepatitis B
RxNorm normalized name: HEPATITIS B
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hepatitis B education/promotion curriculum package; administered over 4 class periods before vaccination.
Trial: 1569973
Drug: Standard therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard therapy plus plasmapheresis
Trial: 1569973
Drug: Standard therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard therapy (prednisone and cyclophosphamide)
Trial: 3865246
Drug: 0.5 mg
RxNorm normalized name: biotin 0.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 mg DEX (dexamethasone) administered at 2300 h
Trial: 3865246
Drug: 1.0 mg
RxNorm normalized name: HYDROCORTISONE BUTYRATE 1.0 mg in 1 g TOPICAL CREAM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.0 mg DEX (dexamethasone) administered at 2300 h
Trial: 30484332
Drug: US‐TAP block
FDA approved: no
EMA approved: no
PMDA approved: no
Description: US‐TAP block with 20 mL of 0.35% ropivacaine
Trial: 27511476
Drug: Nifedipine GITS
RxNorm normalized name: Nifedipine
DrugBank: Nifedipine (DB01115)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nifedipine GITS (N) monotherapy
Trial: 25527666
Drug: Serum 25(OH)D
RxNorm normalized name: 1α,25(OH)2D3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Serum 25(OH)D concentrations ≥30 ng/mL for HIV-infected infants
Trial: 25527666
Drug: Serum 25(OH)D
RxNorm normalized name: 1α,25(OH)2D3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Serum 25(OH)D concentrations ≥30 ng/mL for HIV-exposed infants
Trial: 25527666
Drug: Serum 25(OH)D
RxNorm normalized name: 1α,25(OH)2D3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Serum 25(OH)D concentrations <10 ng/mL for HIV-infected infants
Trial: 25527666
Drug: Serum 25(OH)D
RxNorm normalized name: 1α,25(OH)2D3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Serum 25(OH)D concentrations <10 ng/mL for HIV-exposed infants
Trial: 21655990
Drug: Metformin (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin (500 mg o.d. for 1 week, then 1 g b.d. for 1 week)
Trial: 21655990
Drug: Internal control
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Internal control (no treatment for 1 week)
Trial: 21655990
Drug: Metformin (same
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin (same dose regimen as above)
Trial: 14601275
Drug: 1.5 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.5 mg/kg propofol (group A)
Trial: 14601275
Drug: 2.0 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.0 mg/kg propofol (group B)
Trial: 14601275
Drug: 0.4 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.4 mg/kg propofol (test-dose)
Trial: 14601275
Drug: Correlation between
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Correlation between test-dose and induction-dose
Trial: 10854683
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg isradipine plus 5 mg enalapril
Trial: 10854683
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg isradipine
Trial: 10854683
Drug: combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: combination of isradipine plus enalapril
Trial: 1425871
Drug: Acipimox (doses:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acipimox (doses: 31.2, 62.5, 125.0, 250.0 mg)
Trial: 6378522
Drug: Aspirin (325
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin (325 mg t.i.d.) and dipyridamole (75 mg t.i.d.)
Trial: 26853497
Drug: Cognitive behaviour
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive behaviour treatment program (Cool Kids)
Trial: 24525115
Drug: MOSF (15%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MOSF (15% Fish oil, 30% Medium‐chain triglycerides, 25% Olive oil, 30% Soybean oil) at 3.5 g kg(‐1) d(‐1)
Trial: 24525115
Drug: MOSF (15%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MOSF (15% Fish oil) at 2.5 g kg(‐1) d(‐1)
Trial: 8388918
Drug: Vincristine (VCR)
DrugBank: Vincristine (DB00541)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vincristine (VCR) and Dactinomycin (AMD) for 38 weeks (L)
Trial: 3551160
Drug: Multiple chemotherapeutic
RxNorm normalized name: Other chemotherapeutics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multiple chemotherapeutic agents
Trial: 3551160
Drug: Single chemotherapeutic
RxNorm normalized name: Other chemotherapeutics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single chemotherapeutic agents
Trial: 21853386
Drug: Clodronate 300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clodronate 300 mg i.v. for 7 days, followed by clodronate i.m. 100 mg for 14 days every 3 months (Group A)
Trial: 21853386
Drug: Hydroxychloroquine 400
RxNorm normalized name: hydroxychloroquine 400 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydroxychloroquine 400 mg daily for 30 days, followed by 200 mg daily for the next 11 months (Group B)
Trial: 15649655
Drug: 3 cups
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 cups (450 mL) of filtered coffee for 3 weeks
Trial: 15649655
Drug: 6 cups
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6 cups (900 mL) of filtered coffee for 3 weeks
Trial: 15649655
Drug: 1 cup
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 cup (150 mL) of coffee (single dose)
Trial: 15649655
Drug: 2 cups
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 cups (300 mL) of coffee (single dose)
Trial: 12469330
Drug: Colestipol hydrochloride
RxNorm normalized name: Colestipol Hydrochloride
DrugBank: Colestipol (DB00375)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Colestipol hydrochloride (colestipol) administered with diltiazem SR
Trial: 17803064
Drug: HEP1 (human
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HEP1 (human ezrin peptide 324‐337; TEKKRRETVEREKE) monotherapy
Trial: 16024305
Drug: Rabeprazole 20
RxNorm normalized name: RABEprazole 20 mg oral delayed release tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rabeprazole 20 mg once daily for 4-8 weeks
Trial: 8880815
Drug: Oral transmucosal
RxNorm normalized name: Thrive, 2 mg oral transmucosal gum
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral transmucosal ketamine (5‐6 mg.kg‐1)
Trial: 8880815
Drug: Intranasal ketamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal ketamine (5‐6 mg.kg‐1)
Trial: 8880815
Drug: Intramuscular ketamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular ketamine (5‐6 mg.kg‐1)
Trial: 3930990
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose naloxone (2 mg/kg)
Trial: 3930990
Drug: Low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose naloxone (0.4 mg, approx. 5 micrograms/kg)
Trial: 3663882
Drug: 4 mg
RxNorm normalized name: lutein 4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 mg controlled-release (CR) albuterol tablet (q12h)
Trial: 3663882
Drug: 2 mg
RxNorm normalized name: iodine 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mg conventional albuterol tablet (q6h)
Trial: 15193678
Drug: Enoxaparin 1
RxNorm normalized name: ENOXAPARIN 100MG/ML INJ
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enoxaparin 1 mg/kg twice daily
Trial: 31665385
Drug: Daily supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily supplementation with an egg and 150 mL of cow milk for 90 days, and 1 sachet of multiple micronutrient powder for 60 days.
Trial: 20463260
Drug: Intervention group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intervention group (tailored exercise prescription + transtheoretical behavior change counseling)
Trial: 20463260
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (exercise prescription alone)
Trial: 12701337
Drug: APAP treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: APAP treatment (n = 50)